Aim: Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are considered among the most potent antiviral agents for the treatment of chronic hepatitis B infection. We aimed to compare treatment efficacy and safety of ETV and TDF in nucleoside-naïve chronic hepatitis B patients.
INTRODUCTION

C
URRENTLY AVAILABLE TREATMENTS for patients with chronic hepatitis B (CHB) include individualized single-agent therapy with pegylated interferon-α or nucleos(t)ide analogue (NA) polymerase inhibitors. 1, 2 Pegylated interferon is used for a finite duration of treatment that, when successful, may lead to long-term immune control without the need for further antiviral therapy. 3 Over the past two decades, treatment of CHB has greatly improved with the availability of oral NA drugs including lamivudine, adefovir, entecavir (ETV), telbivudine, clevudine (exclusively in Korea, the Philippines, and Thailand), and tenofovir, which target particular sites of hepatitis B viral polymerases. 4, 5 The sustained on-treatment suppression of serum hepatitis B virus (HBV) DNA to very low or undetectable levels by these drugs has been shown to be associated with the prevention of progression of liver disease and reduced development of hepatocellular carcinoma (HCC). [5] [6] [7] Among the approved NAs, ETV and tenofovir disoproxil fumarate (TDF) have potent antiviral activity 7 and are currently recommended as first-line monotherapies for CHB. 2, 4 Both drugs achieved high rates of complete HBV DNA suppression and alanine aminotransferase (ALT) normalization in phase III studies in both hepatitis B e antigen (HBeAg)-positive and in HBeAg-negative patients and showed maintenance of viral suppression in longterm studies. [8] [9] [10] [11] [12] [13] [14] [15] In addition, both ETV and TDF are associated with low rates of resistance development in NA-naïve patients during long-term therapy. [16] [17] [18] Both drugs showed favorable safety profiles over 5 years. 19, 20 Published randomized controlled trials comparing both highly potent drugs for treatment of CHB patients have been limited. Evidence to support the efficacy and safety of each drug is currently limited to small-scale or retrospective studies. [21] [22] [23] [24] This has left clinicians to make their own judgments about the relative efficacy of treatments for which head-to-head trials are unclear. The objective of this study was to evaluate the efficacy and safety of ETV therapy compared with TDF in NA-naïve patients with HBeAgpositive or HBeAg-negative CHB. . We invited all NA-naïve CHB patients aged 20-65 years to participate in this protocol. A total of 411 naïve CHB patients were enrolled to receive either ETV 0.5 mg or TDF 300 mg daily. The inclusion criteria included adult CHB patients who were compensated with either HBeAg-positive or HBeAg-negative and initial HBV DNA greater than 2000 IU/mL with evidence of chronic hepatitis. The exclusion criteria included coinfection with hepatitis C virus and/or HIV, concurrent malignancy, and decompensate cirrhosis. Females who were pregnant, lactating, or unable to use effective birth control were excluded. Written informed consent was obtained from each participating patient. All patients were followed every 3 months to week 144.
MATERIALS AND METHODS
Patient
Virological, biochemical, and serological studies
Liver biochemistry, HBV serological markers, HBV DNA, quantitative hepatitis B surface antigen (qHBsAg), and HBeAg levels were serially measured at baseline and every 24 weeks. Virological response was defined as ALT normalization, serum HBV DNA level undetectable, and HBeAg seroconversion in HBeAg-positive patients. Hepatitis B virus DNA was done using COBAS AmpliPrep-COBAS TaqMan (Roche Molecular Systems, Branchburg, NJ, USA) assay with a lower limit of detection of 20 IU/mL. A level of 20 IU/mL was used for patients with undetectable HBV DNA. For measurement of HBsAg, samples were quantified according to research protocol using the Elecsys HBsAg II assay (Roche Diagnostics, Mannheim, Germany). Serum and urine creatinine measurements utilized enzymatic methods. Hepatitis B e antigen was expressed in serum over the positive cut-off ratio using the Elecsys system. Serum phosphate and urine phosphate were measured using a COBAS 6000 analyzer (Roche Diagnostics) and the ranges were 0.31-20 mg/dL and 3.4-285 mg/dL, respectively. However, serum and urine phosphate was collected only at week 96 and 144.
Efficacy and safety assessment
Efficacy end-points included plasma HBV DNA, ALT, and HBeAg/HBsAg loss or seroconversion. The co-primary end-points in the study were safety-related: tolerability failures and confirmed estimated glomerular filtration rate (eGFR) decrease ≥20% or serum phosphorus values <2.0 mg/dL. Urine fractional excretion of phosphorus was also calculated to determine tubular dysfunction of each drug. The fractional excretion of phosphorus (FEPi) was calculated as [urine phosphorus (mEq/L)/serum phosphorus (mg/dL)] × [serum creatinine (mg/dL)/urine creatinine (mEq/L)] × 100. Adverse events (AEs), serious AEs, laboratory abnormalities, deaths, and discontinuation of the study drugs due to AEs were evaluated.
Statistical analysis
To determine changes of HBV DNA in serum, HBV DNA measured in IU/mL was calculated into logarithmic scales. Descriptive statistics were reported as proportion (%) for categorical variables and means ± standard deviations for continuous variables. The χ 2 -test or Fisher's exact test was used to compare categorical data and the independent t-test or Mann-Whitney U-test for continuous data. Wilcoxon's signed ranks test was used for paired continuous data. Logistic regression analysis was used to identify predictive factors of adequate HBV DNA suppression. All data were processed and analyzed by using Stata/SE version 12 software, (StataCorp LP, College Station, TX, USA).
RESULTS
Baseline characteristics of patients
A LL PATIENTS' CHARACTERISTICS and laboratory values at the time of study entry are summarized in Table 1 . Eleven patients became pregnant during treatment, five in the ETV group and six in the TDF group, and they were excluded from the protocol. At week 144, there were 400 naïve CHB patients: 200 patients were enrolled to receive ETV 0.5 mg and 200 patients for TDF 300 mg daily. Hepatitis B e antigen was positive in 95/200 patients (47.5%) receiving ETV therapy and 92/200 patients (46.0%) receiving TDF therapy. There were no differences in baseline characteristics of the two groups including age, sex, body mass index, HBV DNA, ALT levels, cirrhosis at baseline, eGFR, qHBsAg, and underlying diseases including hypertension and diabetes mellitus, as shown in Table 1 . Mean age of the patients in both groups was 41 years (36.8 years in HBeAg-positive patients and 45.4 years in HBeAg-negative patients); 56.5% and 60.5% of patients were male in the TDF and ETV treatment groups, respectively. Hepatitis B virus DNA in the HBeAgpositive group was approximately 2 log 10 IU/mL higher than in the HBeAg-negative group.
Virological, biochemical, and serologic responses to ETV and TDF There was 4.5-4.6 log 10 IU/mL decline in HBV DNA at weeks 96 and 144, which was not statistically significant in either group. Undetectable HBV DNA at 96 and 144 weeks of treatment was not different between groups ( Table 2 ). The proportions of patients who had ALT normalization at week 144 was not statistically different between the two groups (88.5% vs. 86.5%, P = 0.55). Among patients who were HBeAg-positive at baseline, HBe seroconversion occurred in 26 (27.4%) of the ETV group and 31 (33.7%) of the TDF group at 144 weeks. The qHBsAg levels (log 10 IU/mL) from baseline to weeks 48, 96, and 144 are shown in Figure 1 . The qHBsAg levels dropped significantly from baseline in both treatment groups, with mean drops of 0.4 and 0.5 log 10 IU/mL at 144 weeks for ETV and TDF, respectively, with no statistical significance between the two groups. Five patients experienced HBsAg loss during the treatment, two in the ETV group at weeks 48 and 120, and three in the TDF group at weeks 48, 72, and 144. Of these five patients, there was one HBeAg-positive patient in each treatment group. 
Safety end-points at weeks 96 and 144
No major clinical side-effects were reported during treatment with either ETV or TDF. The most common AEs reported while on treatment with ETV or TDF were headache, dizziness, minor rash, fatigue, upper abdominal pain, and back pain, most of which were mild in severity. Two patients developed allergic reaction (grade 2 allergy considered related to study drug) with severe skin itching and rash along extremities and trunk. This was resolved in 2 weeks after treatment with topical steroid and antihistamine. No patients discontinued the study drug because of minor side-effects. Protocol-defined criteria for renal toxicity from study drug are shown in Table 3 . No patient had confirmed serum phosphorus <2.0 mg/dL through 144 weeks of treatment.
Mean eGFR dropped during treatment weeks 48, 96, and 144 in both treatment groups but was not statistically significant, as shown in Figure 2 . Decreases in eGFR ≥20% at weeks 48, 96, and 144 in both treatment groups were compared. There were more patients in the TDF group with a drop in eGFR ≥20%, however, it was statistically significant only at treatment week 96 (Table 3) . No patients required TDF dose adjustment because of decreased eGFR. The FEPi was also calculated to determine tubular dysfunction of each drug at weeks 96 and 144. The FEPi was not statistically different at week 96 but was significantly higher for the TDF group at week 144.
Factors predictive of viral suppression at weeks 96 and 144
Percentages of patients with HBV DNA <20 IU/mL are shown in Table 2 . Both ETV and TDF groups achieved high rates of viral suppression at weeks 96 and 144. Factors predictive of virological response (HBV DNA <20 IU/mL) at weeks 96 and 144 are shown in Table 4 . Potential baseline predictive factors included in univariate analyses were age, gender, serum HBV DNA level (log 10 IU/mL), HBeAg positivity, serum ALT level, and treatment group. Univariate analysis showed that advanced age at baseline was associated with adequate HBV DNA suppression at treatment weeks 96 and 144, whereas high HBV DNA level and HBeAg positivity at baseline were predictive for inadequate HBV suppression at treatment weeks 96 and 144. However, multivariate analysis showed that only baseline HBV DNA level was still a significant negative predictor at week 96 (coefficient = À0.53 [À0.83 to À0.24], P < 0.001) and advanced age was a positive predictor at week 144. One patient had virological breakthrough after 48 weeks of treatment in the TDF group because of poor compliance and returned to suppressed level without hepatitis B flare. No patients died due to liver disease progression. There were two female and two male patients who developed small HCC after 12-36 months of ETV treatment and one female CHB patient in the TDF group was diagnosed with HCC 6 months after treatment initiation. 
DISCUSSION
I
N THIS STUDY, we carried out a randomized controlled trial to compare treatment efficacy and safety of ETV and TDF in nucleoside-naïve CHB patients at 144 weeks of treatment. Standard CHB efficacy assessments included HBV DNA suppression, ALT normalization, and HBeAg loss or seroconversion in HBeAg-positive patients; HBsAg loss or seroconversion was the ultimate goal. No statistically significant differences were revealed between the two study drugs for all efficacy end-points. The results of our analysis suggested that, in treatment-naïve CHB individuals, ETV and TDF are very effective to suppress HBV DNA throughout 144 weeks of study. Although there was a significant drop of mean qHBsAg from baseline, only 1.0-1.5% of patients had HBsAg loss during 144 weeks of treatment. This means that if the treatment end-point is HBsAg loss, it will take several more years of treatment until the patients have HBsAg loss. In order to identify predictive factors of successful HBV DNA suppression, we carried out a univariate analysis. We found that advanced age was a predictive factor for adequate HBV DNA suppression, whereas high baseline HBV DNA level and HBeAg positivity were negative predictive factors for adequate HBV DNA suppression at weeks 96 and 144. All of these predictors may relate to high HBV DNA level, as HBeAgpositive patients had much higher baseline HBV DNA levels than HBeAg-negative patients, advanced age was significant predictor because there were more HBeAg negative and low baseline HBV DNA patients in this group. Multivariate analysis found that only low baseline HBV DNA was a predictive factor of adequate DNA suppression at week 96 and advanced age at week 144.
Both drugs were safe and well tolerated. Mean eGFR dropped during treatment in both treatment groups and there was no statistical difference. When we analyzed the patients who had confirmed eGFR decrease ≥20%, the decrease was found to be higher in the TDF group and reached statistical significance at treatment weeks 48 and 96; however, it was not statistically significant at treatment week 144. This result showed that decreased eGFR was not consistent. No patient required TDF dose adjustment; even continued TDF treatment through to week 144 did not result in further decreases in eGFR. No patient developed persistent hypophosphatemia during 144 weeks of treatment. Fractional excretion of phosphate was significantly higher in the TDF group at week 144, however, there was no baseline FEPi and no patient had persistently low serum phosphorus. In general, the safety and tolerability of both ETV and TDF were excellent independently, despite the decrease of eGFR over time, which was observed in both treatment groups. This is consistent with other prospective clinical trials in treatment-naïve patients and with safety data collected over 5 years. 20 There is a general consensus that TDF is associated with mild renal impairment only in individuals with pre-existing risk factors for renal disease including diabetes, co-infection with HIV or hepatitis C virus, baseline renal insufficiency, and co-treatment with nephrotoxic medications. [25] [26] [27] Patients at greatest risk should be closely monitored for renal tubular function and dose modification may be required. 17, 28 The severity and risk of TDF-associated renal toxicity in CHB patients without renal disease or risk factors for renal disease is not established. 17, 25 In this study, we tried to identify whether the drop in eGFR in both treatment groups was related to pre-existing hypertension or diabetes mellitus but we did not find any statistical difference in patients with these pre-existing diseases in either treatment group. This may be because there were not many patients with preexisting diseases.
The novel tenofovir prodrug tenofovir alafenamide delivers 90% lower plasma tenofovir compared with standard TDF. This pharmacology might reduce the off-target effects of TDF, in particular renal and bone toxicity. 29 The significant difference in tubular dysfunction risk and creatinine clearance decline was reported with tenofovir alafenamide versus TDF in phase III non-inferiority trials. 30 Safety results in CHB patients are similar to those previously reported with tenofovir alafenamide in HIVinfected patients. 31, 32 Resistance to ETV or TDF was not detected during the study period, suggesting that continued viremia may be due to high baseline viral load and some due to nonadherence, although genotypic analysis of HBV resistance variants was not undertaken. In prior studies that evaluated the long-term efficacy of TDF in 131 patients, virological breakthrough was not observed. 33 Resistance to TDF has not been observed through 6 years of continuous use in CHB patients. 34 In another study by Chang et al., ETV resistance emerged in only one patient during 5 years of followup, therefore they suggested extended long-term therapy with ETV through to 5 years in HBeAg-positive CHB. 8 There are some limitations to this study. First, the follow-up period was only 3 years, so we could not establish long-term benefit of treatment, such as prevention of liver decompensation or HCC, nor the effect on patient survival. Longer periods of treatment and larger numbers of patients are currently being investigated in our prospective study. Second, we did not have baseline serum and urine phosphate levels at the beginning of the study as there was no concern about renal and bone complications of nucleotide analogues until a few years after TDF was marketed. However, when we amended the protocol, both groups of patients had been exposed to ETV or TDF for the same duration. Finally, we did not have HBV genotype data, which can be applicable in other treatment populations. A recent study showed that HBV genotype in Thailand was 87% genotype C and 10% genotype B, 35 which means this data mainly represented HBV genotype C.
In conclusion, 3 years of treatment with antiviral therapy, ETV or TDF, showed potent antiviral activity against HBV and the efficacy of both drugs was comparable. Both drugs were safe without significant AEs. We did not find any significant renal toxicity in CHB patients who received TDF or ETV. However, a longer period of follow-up is needed to assess the resistance rate and safety profiles of each drug during long-term use.
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